Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
•Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the treatment population. [Display omitted] Paroxysmal...
Uloženo v:
| Vydáno v: | Blood advances Ročník 7; číslo 11; s. 2468 - 2478 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
13.06.2023
The American Society of Hematology |
| Témata: | |
| ISSN: | 2473-9529, 2473-9537, 2473-9537 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the treatment population.
[Display omitted]
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor–naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, −1870.5 U/L; control, −400.1 U/L; difference, −1470.4 U/L; 95% CI, −2113.4 to −827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor–naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. |
|---|---|
| AbstractList | Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor–naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, −1870.5 U/L; control, −400.1 U/L; difference, −1470.4 U/L; 95% CI, −2113.4 to −827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor–naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor-naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, -1870.5 U/L; control, -400.1 U/L; difference, -1470.4 U/L; 95% CI, -2113.4 to -827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor-naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601.Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor-naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, -1870.5 U/L; control, -400.1 U/L; difference, -1470.4 U/L; 95% CI, -2113.4 to -827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor-naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. •Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the treatment population. [Display omitted] Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor–naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, −1870.5 U/L; control, −400.1 U/L; difference, −1470.4 U/L; 95% CI, −2113.4 to −827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor–naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor-naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, -1870.5 U/L; control, -400.1 U/L; difference, -1470.4 U/L; 95% CI, -2113.4 to -827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor-naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. • Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control. • Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the treatment population. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy approved for adults with PNH (United States), adults with PNH with inadequate response or intolerance to a C5 inhibitor (Australia), and adults with anemia despite C5-targeted therapy for ≥3 months (European Union). PRINCE was a phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of pegcetacoplan vs control (supportive care only; eg, blood transfusions, corticosteroids, and supplements) in complement inhibitor–naive patients with PNH. Eligible adults receiving supportive care only for PNH were randomly assigned and stratified based on their number of transfusions (<4 or ≥4) 12 months before screening. Patients received pegcetacoplan 1080 mg subcutaneously twice weekly or continued supportive care (control) for 26 weeks. Coprimary end points were hemoglobin stabilization (avoidance of >1-g/dL decrease in hemoglobin levels without transfusions) from baseline through week 26 and lactate dehydrogenase (LDH) change at week 26. Overall, 53 patients received pegcetacoplan (n = 35) or control (n = 18). Pegcetacoplan was superior to control for hemoglobin stabilization (pegcetacoplan, 85.7%; control, 0; difference, 73.1%; 95% confidence interval [CI], 57.2-89.0; P < .0001) and change from baseline in LDH (least square mean change: pegcetacoplan, −1870.5 U/L; control, −400.1 U/L; difference, −1470.4 U/L; 95% CI, −2113.4 to −827.3; P < .0001). Pegcetacoplan was well tolerated. No pegcetacoplan-related adverse events were serious, and no new safety signals were observed. Pegcetacoplan rapidly and significantly stabilized hemoglobin and reduced LDH in complement inhibitor–naive patients and had a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04085601. |
| Author | Goh, Yeow Tee Dumagay, Teresita Idrobo, Henry Alvarenga, Paulo Deschatelets, Pascal Wong, Raymond Siu Ming Ajayi, Temitayo Grossi, Federico Kongkabpan, Daolada Comia, Narcisa Sonia Savage, Jessica Francois, Cedric Navarro-Cabrera, Juan Ramon Al-Adhami, Mohammed Gómez-Almaguer, David |
| Author_xml | – sequence: 1 givenname: Raymond Siu Ming surname: Wong fullname: Wong, Raymond Siu Ming email: raymondwong@cuhk.edu.hk organization: Sir YK Pao Centre for Cancer & Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, NT, Hong Kong, Hong Kong – sequence: 2 givenname: Juan Ramon surname: Navarro-Cabrera fullname: Navarro-Cabrera, Juan Ramon organization: Department of Hematology, Edgardo Rebagliati Hospital, Lima, Peru – sequence: 3 givenname: Narcisa Sonia surname: Comia fullname: Comia, Narcisa Sonia organization: Research Center, Mary Mediatrix Medical Center, Lipa, Philippines – sequence: 4 givenname: Yeow Tee orcidid: 0000-0002-7069-0997 surname: Goh fullname: Goh, Yeow Tee organization: Department of Haematology, Singapore General Hospital, Singapore – sequence: 5 givenname: Henry surname: Idrobo fullname: Idrobo, Henry organization: Department of Haematology, Julian Coronel Medical Center, Cali, Colombia – sequence: 6 givenname: Daolada surname: Kongkabpan fullname: Kongkabpan, Daolada organization: Department of Medicine, Songklanagarind Hospital, Songkhla, Thailand – sequence: 7 givenname: David surname: Gómez-Almaguer fullname: Gómez-Almaguer, David organization: Department of Haematology, Dr. José Eleuterio González University Hospital, Monterrey, Mexico – sequence: 8 givenname: Mohammed orcidid: 0000-0003-2021-747X surname: Al-Adhami fullname: Al-Adhami, Mohammed organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 9 givenname: Temitayo surname: Ajayi fullname: Ajayi, Temitayo organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 10 givenname: Paulo surname: Alvarenga fullname: Alvarenga, Paulo organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 11 givenname: Jessica surname: Savage fullname: Savage, Jessica organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 12 givenname: Pascal orcidid: 0009-0001-0123-5528 surname: Deschatelets fullname: Deschatelets, Pascal organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 13 givenname: Cedric surname: Francois fullname: Francois, Cedric organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 14 givenname: Federico surname: Grossi fullname: Grossi, Federico organization: Apellis Pharmaceuticals, Waltham, MA – sequence: 15 givenname: Teresita surname: Dumagay fullname: Dumagay, Teresita organization: Department of Cellular Therapeutics, Makati Medical Centre, Makati City, Philippines |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36848639$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1yFCEQxykrlolrXsGao5eNwHwAFz-SMmpVqvSgZwqYnl2UgRGY1b35DnlDn0S2Nokmpz3RTXf__vDvp-jIBw8IVQSfEcLpS-1C6FW_Ud5AOqOYUowFoeIROqENq5eirdnRXUzFMTpN6RvGmLCubgV9go7rjje8q8UJip9hZSArEyanfGWCzzG4VK1hDG6bbKrs7nacHIzgc8nWVtsc4p_f117ZDVSTyrZUUvXT5nXJYvi1TaNylQ8mz9GXaAdbuaCtn6NVz9DjQbkEpzfnAn29fPfl4sPy6tP7jxdvr5amfCAveW0a3Q61JkIP1AjSNkNHoeWNAdabAYPWHdGMNbXQoAasNVOswT0buDK8rxfo9Z47zXqE3pRHRuXkFO2o4lYGZeX9irdruQobSTBtCG9ZIby4IcTwY4aU5WiTAVecgjAnSRnHrGtF8XWBnv8vdqdy63RpeLVvMDGkFGGQxuZi3c5wZV0Rlbvtynvblf-2WwD8AeBW44DR8_0oFLs3FqJMpuzMQG8jmCz7YA-BvHkAMc56a5T7DtvDEH8B7bri1A |
| CitedBy_id | crossref_primary_10_7759_cureus_81134 crossref_primary_10_1007_s40268_024_00463_9 crossref_primary_10_3390_ijms25179477 crossref_primary_10_1007_s00277_024_05968_6 crossref_primary_10_1111_ejh_14139 crossref_primary_10_1182_bloodadvances_2024012672 crossref_primary_10_31435_ijitss_3_47__2025_3842 crossref_primary_10_1056_NEJMc2404445 crossref_primary_10_3390_hematolrep16040065 crossref_primary_10_1007_s00467_024_06476_5 crossref_primary_10_1002_jha2_70020 crossref_primary_10_1007_s12325_023_02653_4 crossref_primary_10_1080_1750743X_2024_2433410 crossref_primary_10_1007_s12325_025_03310_8 crossref_primary_10_1007_s40268_024_00500_7 crossref_primary_10_1080_17474086_2024_2440101 crossref_primary_10_2147_JBM_S431493 crossref_primary_10_3390_medicina60060945 crossref_primary_10_1056_NEJMoa2308695 crossref_primary_10_3390_ijms25168591 crossref_primary_10_1371_journal_pone_0306407 crossref_primary_10_1002_ajh_26998 crossref_primary_10_1016_j_blre_2023_101158 crossref_primary_10_1002_ajh_27426 crossref_primary_10_1007_s12325_024_02827_8 crossref_primary_10_1182_blood_2024025176 crossref_primary_10_1182_blood_2024027574 crossref_primary_10_1182_bloodadvances_2024015777 crossref_primary_10_1007_s40265_025_02235_4 crossref_primary_10_3390_ijms25168698 crossref_primary_10_3390_hematolrep15040060 crossref_primary_10_1016_j_bbcan_2025_189436 crossref_primary_10_1016_j_rpth_2024_102416 crossref_primary_10_1111_bjh_20025 crossref_primary_10_1159_000540474 crossref_primary_10_3390_diseases13090298 crossref_primary_10_1182_bloodadvances_2023011691 crossref_primary_10_3390_ijms26125902 |
| Cites_doi | 10.1182/blood-2020-134436 10.3389/fimmu.2019.01157 10.1172/JCI114311 10.1056/NEJMoa2029073 10.1007/s00277-020-04052-z 10.1002/cncr.10245 10.1177/2040620720966137 10.1182/blood-2021-148042 10.3324/haematol.2017.177618 10.1182/blood-2018-09-876136 10.3109/0284186X.2013.879998 10.1007/s00277-022-04903-x 10.3324/haematol.2013.093161 10.1182/blood-2008-11-189944 10.1053/j.seminhematol.2018.05.014 10.1182/blood-2018-09-876805 10.1038/s41409-021-01372-0 10.1002/j.1460-2075.1994.tb06240.x 10.1056/NEJMoa061648 10.1182/blood-2007-06-094136 10.1182/blood-2005-04-1717 10.1016/S0885-3924(02)00529-8 10.1111/j.1365-2141.2012.09166.x 10.1007/s00277-021-04715-5 10.1007/s12185-013-1404-y 10.1182/blood-2021-144554 |
| ContentType | Journal Article |
| Copyright | 2023 The American Society of Hematology 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 The American Society of Hematology |
| Copyright_xml | – notice: 2023 The American Society of Hematology – notice: 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. – notice: 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 The American Society of Hematology |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1182/bloodadvances.2022009129 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2473-9537 |
| EndPage | 2478 |
| ExternalDocumentID | PMC10241857 36848639 10_1182_bloodadvances_2022009129 S2473952923001027 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | .1- .FO 0R~ 53G AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ H13 HYE OK1 ROL RPM THE W2D Z5R 6I. AAFTH AFCTW AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c537t-83c4b5f3b19bf2c9154f62e584ce7dcf0ebb61b77439beaf0bb7a740d7f8ac8d3 |
| ISICitedReferencesCount | 42 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001019165100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2473-9529 2473-9537 |
| IngestDate | Tue Sep 30 17:13:23 EDT 2025 Wed Oct 01 17:17:06 EDT 2025 Mon Jul 21 06:06:17 EDT 2025 Sat Nov 29 03:31:43 EST 2025 Tue Nov 18 22:36:10 EST 2025 Sat Aug 05 16:01:08 EDT 2023 Tue Aug 26 16:33:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c537t-83c4b5f3b19bf2c9154f62e584ce7dcf0ebb61b77439beaf0bb7a740d7f8ac8d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-7069-0997 0009-0001-0123-5528 0000-0003-2021-747X |
| OpenAccessLink | http://dx.doi.org/10.1182/bloodadvances.2022009129 |
| PMID | 36848639 |
| PQID | 2780765976 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10241857 proquest_miscellaneous_2780765976 pubmed_primary_36848639 crossref_citationtrail_10_1182_bloodadvances_2022009129 crossref_primary_10_1182_bloodadvances_2022009129 elsevier_sciencedirect_doi_10_1182_bloodadvances_2022009129 elsevier_clinicalkey_doi_10_1182_bloodadvances_2022009129 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-13 |
| PublicationDateYYYYMMDD | 2023-06-13 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood advances |
| PublicationTitleAlternate | Blood Adv |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc The American Society of Hematology |
| Publisher_xml | – name: Elsevier Inc – name: The American Society of Hematology |
| References | (bib29) 2022 Schrezenmeier, Kulasekararaj, Mitchell (bib16) 2021; 138 Wong, Ignatova, Pullon (bib26) 2020; 136 Cella, Lai, Chang, Peterman, Slavin (bib23) 2002; 94 Parker, Omine, Richards (bib1) 2005; 106 Griffin, Kelly, Pike (bib20) 2020; 1 Hillmen, Szer, Weitz (bib25) 2021; 384 Hoffman, Machaidze, Yeh, Weitz (bib32) 2021; 138 Hill, Sapsford, Scally (bib5) 2012; 158 Bektas, Copley-Merriman, Khan, Sarda, Shammo (bib19) 2020; 26 Wong, Pullon, Amine (bib21) 2022; 101 Hinz, Singer, Brähler (bib24) 2014; 53 Peacock-Young, Macrae, Newton, Hill, Ariëns (bib4) 2018; 103 Lee, Sicre de Fontbrune, Wong Lee Lee (bib11) 2019; 133 Kanakura, Ohyashiki, Shichishima (bib13) 2013; 98 Schrezenmeier, Muus, Socié (bib6) 2014; 99 Kulasekararaj, Hill, Rottinghaus (bib12) 2019; 133 Holguin, Wilcox, Bernshaw, Rosse, Parker (bib3) 1989; 84 Schrezenmeier, Röth, Araten (bib7) 2020; 99 Dingli, Matos, Lehrhaupt (bib18) 2022; 101 Debureaux, Kulasekararaj, Cacace (bib31) 2021; 56 Notaro, Sica (bib15) 2018; 55 Schrezenmeier, Kulasekararaj, Mitchell (bib27) 2020; 11 (bib28) 2023 Bessler, Mason, Hillmen (bib2) 1994; 13 Risitano, Marotta, Ricci (bib8) 2019; 10 McKinley, Richards, Munir (bib17) 2017; 130 Risitano, Notaro, Marando (bib14) 2009; 113 Cella, Eton, Lai, Peterman, Merkel (bib22) 2002; 24 Brodsky, Young, Antonioli (bib10) 2008; 111 Hillmen, Young, Schubert (bib9) 2006; 355 (bib30) 2022 Brodsky (2023061219031565500_bib10) 2008; 111 2023061219031565500_bib30 Peacock-Young (2023061219031565500_bib4) 2018; 103 Hillmen (2023061219031565500_bib9) 2006; 355 Holguin (2023061219031565500_bib3) 1989; 84 Hinz (2023061219031565500_bib24) 2014; 53 Lee (2023061219031565500_bib11) 2019; 133 Debureaux (2023061219031565500_bib31) 2021; 56 Schrezenmeier (2023061219031565500_bib7) 2020; 99 Griffin (2023061219031565500_bib20) 2020; 1 2023061219031565500_bib28 Hillmen (2023061219031565500_bib25) 2021; 384 Schrezenmeier (2023061219031565500_bib6) 2014; 99 McKinley (2023061219031565500_bib17) 2017; 130 2023061219031565500_bib29 Risitano (2023061219031565500_bib8) 2019; 10 Wong (2023061219031565500_bib26) 2020; 136 Parker (2023061219031565500_bib1) 2005; 106 Hill (2023061219031565500_bib5) 2012; 158 Cella (2023061219031565500_bib23) 2002; 94 Kanakura (2023061219031565500_bib13) 2013; 98 Schrezenmeier (2023061219031565500_bib16) 2021; 138 Bessler (2023061219031565500_bib2) 1994; 13 Dingli (2023061219031565500_bib18) 2022; 101 Notaro (2023061219031565500_bib15) 2018; 55 Cella (2023061219031565500_bib22) 2002; 24 Wong (2023061219031565500_bib21) 2022; 101 Risitano (2023061219031565500_bib14) 2009; 113 Schrezenmeier (2023061219031565500_bib27) 2020; 11 Kulasekararaj (2023061219031565500_bib12) 2019; 133 Bektas (2023061219031565500_bib19) 2020; 26 Hoffman (2023061219031565500_bib32) 2021; 138 |
| References_xml | – volume: 384 start-page: 1028 year: 2021 end-page: 1037 ident: bib25 article-title: Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med – volume: 56 start-page: 2600 year: 2021 end-page: 2602 ident: bib31 article-title: Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study publication-title: Bone Marrow Transplant – volume: 101 start-page: 1971 year: 2022 end-page: 1986 ident: bib21 article-title: Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria publication-title: Ann Hematol – volume: 138 start-page: 2175 year: 2021 ident: bib32 article-title: Evaluation of the long-term safety and efficacy of pegcetacoplan treatment for paroxysmal nocturnal hemoglobinuria patients: an extension study [abstract] publication-title: Blood – volume: 99 start-page: 922 year: 2014 end-page: 929 ident: bib6 article-title: Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry publication-title: Haematologica – volume: 133 start-page: 530 year: 2019 end-page: 539 ident: bib11 article-title: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study publication-title: Blood – volume: 13 start-page: 110 year: 1994 end-page: 117 ident: bib2 article-title: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene publication-title: EMBO J – volume: 1 year: 2020 ident: bib20 article-title: A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? publication-title: Ther Adv Rare Dis – year: 2022 ident: bib30 article-title: Department of Health and Aged Care, Therapeutic Goods Administration. Australian public assessment report for pegcetacoplan – volume: 130 start-page: 3471 year: 2017 ident: bib17 article-title: Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome [abstract] publication-title: Blood – volume: 55 start-page: 130 year: 2018 end-page: 135 ident: bib15 article-title: C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications publication-title: Semin Hematol – volume: 355 start-page: 1233 year: 2006 end-page: 1243 ident: bib9 article-title: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med – year: 2022 ident: bib29 article-title: Swedish Orphan Biovitrum AB – volume: 136 start-page: 3 year: 2020 end-page: 4 ident: bib26 article-title: C3 inhibition with pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria: results from the Paddock and Palomino trials [abstract] publication-title: Blood – volume: 10 start-page: 1157 year: 2019 ident: bib8 article-title: Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT publication-title: Front Immunol – volume: 133 start-page: 540 year: 2019 end-page: 549 ident: bib12 article-title: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study publication-title: Blood – volume: 138 start-page: 2196 year: 2021 ident: bib16 article-title: Predictors for improvement in patient-reported outcomes: post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) [poster] publication-title: Blood – volume: 101 start-page: 251 year: 2022 end-page: 263 ident: bib18 article-title: The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey publication-title: Ann Hematol – volume: 99 start-page: 1505 year: 2020 end-page: 1514 ident: bib7 article-title: Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry publication-title: Ann Hematol – volume: 11 year: 2020 ident: bib27 article-title: One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study publication-title: Ther Adv Hematol – volume: 84 start-page: 1387 year: 1989 end-page: 1394 ident: bib3 article-title: Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria publication-title: J Clin Invest – volume: 24 start-page: 547 year: 2002 end-page: 561 ident: bib22 article-title: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales publication-title: J Pain Symptom Manage – volume: 113 start-page: 4094 year: 2009 end-page: 4100 ident: bib14 article-title: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab publication-title: Blood – year: 2023 ident: bib28 article-title: Apellis Pharmaceuticals – volume: 106 start-page: 3699 year: 2005 end-page: 3709 ident: bib1 article-title: Diagnosis and management of paroxysmal nocturnal hemoglobinuria publication-title: Blood – volume: 98 start-page: 406 year: 2013 end-page: 416 ident: bib13 article-title: Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial publication-title: Int J Hematol – volume: 158 start-page: 409 year: 2012 end-page: 414 ident: bib5 article-title: Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function publication-title: Br J Haematol – volume: 94 start-page: 528 year: 2002 end-page: 538 ident: bib23 article-title: Fatigue in cancer patients compared with fatigue in the general United States population publication-title: Cancer – volume: 103 start-page: 9 year: 2018 end-page: 17 ident: bib4 article-title: The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source publication-title: Haematologica – volume: 111 start-page: 1840 year: 2008 end-page: 1847 ident: bib10 article-title: Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria publication-title: Blood – volume: 26 start-page: S14 year: 2020 end-page: S20 ident: bib19 article-title: Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs publication-title: J Manag Care Spec Pharm – volume: 53 start-page: 958 year: 2014 end-page: 965 ident: bib24 article-title: European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies publication-title: Acta Oncol – volume: 136 start-page: 3 issue: suppl 1 year: 2020 ident: 2023061219031565500_bib26 article-title: C3 inhibition with pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria: results from the Paddock and Palomino trials [abstract] publication-title: Blood doi: 10.1182/blood-2020-134436 – volume: 10 start-page: 1157 year: 2019 ident: 2023061219031565500_bib8 article-title: Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT publication-title: Front Immunol doi: 10.3389/fimmu.2019.01157 – volume: 26 start-page: S14 issue: suppl 12b year: 2020 ident: 2023061219031565500_bib19 article-title: Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs publication-title: J Manag Care Spec Pharm – ident: 2023061219031565500_bib28 – volume: 1 start-page: 2633004020959349 year: 2020 ident: 2023061219031565500_bib20 article-title: A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going? publication-title: Ther Adv Rare Dis – volume: 84 start-page: 1387 issue: 5 year: 1989 ident: 2023061219031565500_bib3 article-title: Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria publication-title: J Clin Invest doi: 10.1172/JCI114311 – volume: 384 start-page: 1028 issue: 11 year: 2021 ident: 2023061219031565500_bib25 article-title: Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa2029073 – volume: 99 start-page: 1505 issue: 7 year: 2020 ident: 2023061219031565500_bib7 article-title: Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry publication-title: Ann Hematol doi: 10.1007/s00277-020-04052-z – volume: 94 start-page: 528 issue: 2 year: 2002 ident: 2023061219031565500_bib23 article-title: Fatigue in cancer patients compared with fatigue in the general United States population publication-title: Cancer doi: 10.1002/cncr.10245 – volume: 11 start-page: 2040620720966137 year: 2020 ident: 2023061219031565500_bib27 article-title: One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study publication-title: Ther Adv Hematol doi: 10.1177/2040620720966137 – volume: 138 start-page: 2175 issue: suppl 1 year: 2021 ident: 2023061219031565500_bib32 article-title: Evaluation of the long-term safety and efficacy of pegcetacoplan treatment for paroxysmal nocturnal hemoglobinuria patients: an extension study [abstract] publication-title: Blood doi: 10.1182/blood-2021-148042 – volume: 103 start-page: 9 issue: 1 year: 2018 ident: 2023061219031565500_bib4 article-title: The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source publication-title: Haematologica doi: 10.3324/haematol.2017.177618 – volume: 133 start-page: 530 issue: 6 year: 2019 ident: 2023061219031565500_bib11 article-title: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study publication-title: Blood doi: 10.1182/blood-2018-09-876136 – volume: 53 start-page: 958 issue: 7 year: 2014 ident: 2023061219031565500_bib24 article-title: European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies publication-title: Acta Oncol doi: 10.3109/0284186X.2013.879998 – volume: 101 start-page: 1971 issue: 9 year: 2022 ident: 2023061219031565500_bib21 article-title: Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria publication-title: Ann Hematol doi: 10.1007/s00277-022-04903-x – volume: 99 start-page: 922 issue: 5 year: 2014 ident: 2023061219031565500_bib6 article-title: Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry publication-title: Haematologica doi: 10.3324/haematol.2013.093161 – volume: 113 start-page: 4094 issue: 17 year: 2009 ident: 2023061219031565500_bib14 article-title: Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab publication-title: Blood doi: 10.1182/blood-2008-11-189944 – volume: 55 start-page: 130 issue: 3 year: 2018 ident: 2023061219031565500_bib15 article-title: C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications publication-title: Semin Hematol doi: 10.1053/j.seminhematol.2018.05.014 – volume: 130 start-page: 3471 issue: suppl 1 year: 2017 ident: 2023061219031565500_bib17 article-title: Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome [abstract] publication-title: Blood – volume: 133 start-page: 540 issue: 6 year: 2019 ident: 2023061219031565500_bib12 article-title: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study publication-title: Blood doi: 10.1182/blood-2018-09-876805 – volume: 56 start-page: 2600 issue: 10 year: 2021 ident: 2023061219031565500_bib31 article-title: Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study publication-title: Bone Marrow Transplant doi: 10.1038/s41409-021-01372-0 – volume: 13 start-page: 110 issue: 1 year: 1994 ident: 2023061219031565500_bib2 article-title: Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06240.x – volume: 355 start-page: 1233 issue: 12 year: 2006 ident: 2023061219031565500_bib9 article-title: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria publication-title: N Engl J Med doi: 10.1056/NEJMoa061648 – volume: 111 start-page: 1840 issue: 4 year: 2008 ident: 2023061219031565500_bib10 article-title: Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria publication-title: Blood doi: 10.1182/blood-2007-06-094136 – volume: 106 start-page: 3699 issue: 12 year: 2005 ident: 2023061219031565500_bib1 article-title: Diagnosis and management of paroxysmal nocturnal hemoglobinuria publication-title: Blood doi: 10.1182/blood-2005-04-1717 – volume: 24 start-page: 547 issue: 6 year: 2002 ident: 2023061219031565500_bib22 article-title: Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(02)00529-8 – ident: 2023061219031565500_bib29 – volume: 158 start-page: 409 issue: 3 year: 2012 ident: 2023061219031565500_bib5 article-title: Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2012.09166.x – volume: 101 start-page: 251 issue: 2 year: 2022 ident: 2023061219031565500_bib18 article-title: The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey publication-title: Ann Hematol doi: 10.1007/s00277-021-04715-5 – volume: 98 start-page: 406 issue: 4 year: 2013 ident: 2023061219031565500_bib13 article-title: Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial publication-title: Int J Hematol doi: 10.1007/s12185-013-1404-y – volume: 138 start-page: 2196 issue: suppl 1 year: 2021 ident: 2023061219031565500_bib16 article-title: Predictors for improvement in patient-reported outcomes: post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) [poster] publication-title: Blood doi: 10.1182/blood-2021-144554 – ident: 2023061219031565500_bib30 |
| SSID | ssj0001763592 |
| Score | 2.4230103 |
| Snippet | •Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s... Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis. Pegcetacoplan is the first C3-targeted therapy... • Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control. • Pegcetacoplan’s... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2468 |
| SubjectTerms | Adult Antibodies, Monoclonal, Humanized - adverse effects Clinical Trials and Observations Complement Inactivating Agents - adverse effects Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Humans L-Lactate Dehydrogenase |
| Title | Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2473952923001027 https://dx.doi.org/10.1182/bloodadvances.2022009129 https://www.ncbi.nlm.nih.gov/pubmed/36848639 https://www.proquest.com/docview/2780765976 https://pubmed.ncbi.nlm.nih.gov/PMC10241857 |
| Volume | 7 |
| WOSCitedRecordID | wos001019165100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2473-9537 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001763592 issn: 2473-9529 databaseCode: DOA dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6CwcuCMSrC6yCxG0VaJ62xQmteFyoVuwiLafIcRw2UutUfbHc-A_8HP4Nv4SZ-NEGWKkIcYlaN06czFd7ZvzNDCFPaVolUR2JkKeShynL8pCLGKxWpSQIpcorWXfFJuh4zM7P-clg8N3FwqwnVGt2ecln_1XU0AbCxtDZvxC3vyg0wGcQOhxB7HDcSfAn6pNUS5joZhOhHRV9ARrhtDXpRyzz3PDG4dtFUzboube0h0QLZBPZhKs2-m0mkO6ymIJAdYu7DrqLoZy2mFCk0StDVt5sDyMd3vELvNbu6L_vxZcphs2cNqujd27pRIe0WGNKyPBYgJ0-NyTeFW4xYEUkv1nSTg2_d4xVkBYCyT6NX1vetJ2b6KNqPx-dKbXt04ixvkRoQlKNo80F2_S4oHFKk5Bn1kFiJ2-6jdFoeyZOTbkeu6pDZ_bnFYNhBtouSsC9lWcxhh-DImVv1c_HfYrjwGGA8YYJ-egeuRbTjPMte75z8GGqv64otx-4Y5Kx-PlVN7xKPfrd_PmVxbulFp3dIjetPRO8NDi8TQZK3yHzHgYDh8HAYzBosNVhMPAY_PH1W4e-wKEvQPQFG_QFHn1BH313yYfXr86O34a2uEcos4QuQ5bItMzqpIx4WceSgypf57ECfVgqChPESJVlHpUUDeZSiXpUllTQdFTRmgnJquQe2detVg9IIDLQsXlSgaofpSkb8SqRWSUSxQUowHk0JNS900LazPdYgGVSdBYwi4ueNIqNNIYk8j1nJvvLDn24E1vhopthPS4AcDv0feH7Wg3YaLY79n7iUFLAIoE7f0KrdgXnUDaieQamx5DcN6jxz5PkLGVgpwwJ6-HJn4AJ6Pu_6OaiS0QP6MfcV_TgHx75IbmxmQEekf3lfKUek-tyvWwW80OyR8_ZYffH-glnuA7y |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pegcetacoplan+controls+hemolysis+in+complement+inhibitor%E2%80%93naive+patients+with+paroxysmal+nocturnal+hemoglobinuria&rft.jtitle=Blood+advances&rft.au=Wong%2C+Raymond+Siu+Ming&rft.au=Navarro-Cabrera%2C+Juan+Ramon&rft.au=Comia%2C+Narcisa+Sonia&rft.au=Goh%2C+Yeow+Tee&rft.date=2023-06-13&rft.pub=Elsevier+Inc&rft.issn=2473-9529&rft.volume=7&rft.issue=11&rft.spage=2468&rft.epage=2478&rft_id=info:doi/10.1182%2Fbloodadvances.2022009129&rft.externalDocID=S2473952923001027 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2473-9529&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2473-9529&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2473-9529&client=summon |